REG - Trellus Health PLC - Clinical research update on GRITT(tm) methodology

Trellus HealthAnnouncement

17/01/2022 07:05

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220117:nRSQ5473Ya&default-theme=true

RNS Number : 5473Y  Trellus Health PLC  17 January 2022

 ("Trellus Health" or the "Company")

 

Clinical research associates GRITT™ resilience-based methodology

with significantly reduced healthcare utilisation and opioid use in patients
with IBD

 

Research published in Clinical Gastroenterology and Hepatology following 394
IBD patients found significantly improved outcomes with use of GRITT™
methodology, augmenting previous findings

 

LONDON, UK. AND NEW YORK, U.S. (17 January 2022). Trellus Health plc (AIM:
TRLS), which is commercialising a scientifically validated, resilience-based,
connected health solution for chronic condition management, confirms that
clinical research conducted by Trellus Health co-founders Laurie Keefer, PhD,
and Marla Dubinsky, MD, has associated the GRITT™ (Gaining Resilience
Through Transitions) methodology with significantly lower healthcare
utilisation ("HCU(1)"), corticosteroid and opioid use in patients suffering
from Inflammatory Bowel Disease ("IBD"). The clinical research was published
in a recent issue of Clinical Gastroenterology and Hepatology
(https://www.sciencedirect.com/science/article/pii/S1542356521012258) .

 

The peer-reviewed article, entitled "Resilience-based integrated IBD care is
associated with reductions in health care use and opioids(2)," describes the
impact of applying the GRITT™ methodology on resilience, HCU and opioid use
in patients suffering from IBD. 394 low-resilience IBD patients were recruited
from an academic IBD centre, with 184 being GRITT™ participants, and 210 not
using GRITT™. GRITT(TM) IBD Program participants received an average of six
months of multidisciplinary care management in person and via telehealth,
which included a combination of behavioural and nutritional care as well as
medication counselling.

 

The research, conducted at the Susan and Leonard Feinstein IBD Clinical Center
(https://www.mountsinai.org/locations/ibd-center) at The Mount Sinai Hospital
by Dr. Keefer and her team, identified that use of the GRITT™, which
includes the GRITT™( )resilience assessment and personalised treatment
methodology, resulted in a 59% increase in resilience amongst study
participants, which correlated with a 71% reduction in Emergency Department
visits (equivalent to A&E in the UK), and a 94% reduction in unplanned
hospitalisations. The article also found that the GRITT™ Program
participants showed a 49% decrease in opioid use and a 73% reduction in
corticosteroid use at 12 months following the study. The article concludes
that validated methods such as GRITT™ that simultaneously address mind and
body targets, such as resilience evaluation and integrated care management,
may improve patient outcomes and are associated with significant reductions in
HCU and opioid use. This research reinforces and supplements the positive
health outcomes associated with use of the GRITT(TM) Methodology presented in
an award-winning plenary session at the American College of Gastroenterology
(ACG) 2020 Annual Scientific Meeting,

 

Trellus Health holds the exclusive commercial license of the GRITT(TM)
methodology from the Icahn School of Medicine at Mount Sinai, part of the
Mount Sinai Health System in New York, NY, for IBD and seven major chronic
conditions, including heart disease, cancer, kidney disease, diabetes,
autoimmune diseases, COPD and Cystic Fibrosis. The Company intends to scale
GRITT(TM) globally using its proprietary TrellusElevate(TM) platform and
virtual licensed multidisciplinary care teams that include specialist nurses,
behavioral health specialists and registered dietitian nutritionists.

 

Lead author Dr. Laurie Keefer, Co-Founder of Trellus Health, explains:
"Awareness of the importance of treating the whole person when it comes to
chronic disease continues to grow - patients need access to professionals who
can collaborate and consider their disease management goals in context with
the rest of their lives. Patients living with IBD do not have to suffer.
Resilience training works when offered in the setting of quality IBD medical
care. When we do not separate physical and mental health, patients can take
back control and improve their own outcomes, significantly reducing the need
for emergency care and living their best lives. This second study further
confirms this and increases the urgency for getting as many patients access to
much needed psychosocial care as we can."

 

Monique Fayad, CEO of Trellus Health, commented, "We are pleased to see the
positive conclusions of the clinical research recently published in Clinical
Gastroenterology and Hepatology, which augment the data presented in our
co-founders' 2020 ACG presentation. We believe that our resilience-driven
whole-person approach using the GRITT(TM) methodology can dramatically improve
outcomes for patients living with chronic conditions. This will not only lead
to improvements in health and quality of life, but also drive significant
expense reductions associated with costly unplanned care. This research shows
the potential benefit of our integrated virtual care management offering for
millions of people who suffer from IBD around the world, and for healthcare
payers interested in scientifically validated value-based solutions for
complex chronic conditions."

 

The GRITT™( )resilience assessment and personalised treatment methodology
described is based on technology developed by Drs. Dubinsky and Keefer and
licensed to Trellus Health. Mount Sinai and Mount Sinai faculty, including
Marla Dubinsky, MD, and Laurie Keefer, PhD, have a financial interest in
Trellus Health. Mount Sinai has representation on the Trellus Health Board of
Directors.

 

(1)     HCU was defined by the total number of IBD related emergency
department (ED) visits and non-planned, non-surgical IBD-related
hospitalisations collected from the electronic medical record for the year
prior to enrolment in the study and then again 12 months after enrolment.

(2      )
https://www.sciencedirect.com/science/article/pii/S1542356521012258
(https://www.sciencedirect.com/science/article/pii/S1542356521012258)

 

 

For further information please contact:

 

 Trellus Health plc                                       www.trellushealth.com (http://www.trellushealth.com)
 Monique Fayad, CEO                                       Via Walbrook PR
 Julian Baines, Chairman

 Singer Capital Markets (Nominated Adviser & Broker)      Tel: 020 7496 3000
 Aubrey Powell / Jen Boorer

 Walbrook PR Limited                                      Tel: 020 7933 8780 or trellus@walbrookpr.com (mailto:trellus@walbrookpr.com)
 Paul McManus / Sam Allen                                 Mob: 07980 541 893 / 07502 558 258

 

About Trellus Health plc (www.trellushealth.com (http://www.trellushealth.com)
)

Trellus Health (LSE: TRLS) is a leading pioneer in resilience-driven care and
the first digital health company focused on the intersection of chronic
physical conditions and mental health. Trellus Health's digital-first chronic
care management solution integrates convenient access to a licensed
multidisciplinary care team with a suite of tools for resilience assessment,
education and behavior modification, remote monitoring, health maintenance and
prevention. Through its TrellusElevate™ connected care platform and
companion App, the Company enables coordination and delivery of expert
whole-person care, addressing both clinical and behavioral health together, in
context, to improve outcomes and reduce healthcare costs for patients,
employers, and the healthcare system.

 

Trellus Health is commercialising the provision of digital chronic condition
management solutions for employers and health plans that utilise the
scientifically validated resilience-based methodology and a proprietary
HIPAA-compliant technology platform called TrellusElevate™ to coordinate and
deliver personalised care remotely via telehealth. The Company is initially
focused on Inflammatory Bowel Disease ("IBD"), which includes the chronic
incurable conditions of Crohn's Disease and ulcerative colitis, but considers
its approach to have potential utility and demand across many chronic
conditions.

 

The TrellusElevate™ platform is the Company's proprietary connected health
platform that incorporates the proprietary methodology and learnings on
resilience from clinical research and practice conducted at the Mount Sinai
IBD Center for more than five years. The proprietary methodology and
resilience-driven multidisciplinary care model have been scientifically
validated to demonstrate meaningful improvements in patient outcomes, 71%
reduction in Emergency Department (A&E) visits, and 94% reduction in
unplanned hospitalisations, which the directors of the Company believe
indicates the potential for significant cost savings for healthcare payers.
IBD patients treated using the methodology also experienced a 49% reduction in
required opioid use and a 73% reduction in corticosteroid use 12 months
following program completion.

 

The Company was founded by Dr. Marla C. Dubinsky, MD and Dr. Laurie Keefer,
PhD, both with decades of combined experience in IBD and
psychogastroenterology, respectively. Trellus Health's patent-pending
GRITT(TM )resilience assessment and personalized treatment methodology was
developed and validated at the Mount Sinai Health System to build resilience
and wellness for improved outcomes at lower cost.

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under
the ticker TRLS.  For more information on Trellus Health,
visit www.trellushealth.com (https://trellushealth.com/) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RESGPUBAGUPPGMC